Abstract
The Congenital Disorders of Glycosylation (CDG) are a collection of over 20 inherited diseases that impair protein N-glycosylation. The clinical appearance of CDG patients is quite diverse making it difficult for physicians to recognize them. A simple blood test of transferrin glycosylation status signals a glycosylation abnormality, but not the specific defect. An abnormal trasferrin glycosylation pattern suggests that the defect is in either genes that synthesize and add the precursor glycan (Glc3Man9GlcNAc2) to proteins (Type I) or genes that process the protein-bound N-glycans (Type II). Type I defects create unoccupied glycosylation sites, while Type II defects give fully occupied sites with abnormally processed glycans. These types are expected to be mutually exclusive, but a group of patients is now emerging who have variable coagulopathy and hypoglycemia together with a combination of Type I and Type II transferrin features. This surprising finding makes identifying their defects more challenging, but the defects and associated clinical manifestations of these patients suggest that the N-glycosylation pathway has some secrets left to share.
Keywords: serum transferrin, carbohydrate deficient glycoprotein syndrome, MALDI-TOF-MS, LLO species, Electrospray Ionization Mass Spectrometry
Current Molecular Medicine
Title: Congenital Disorders of Glycosylation: CDG-I, CDG-II, and Beyond
Volume: 7 Issue: 4
Author(s): Hudson H. Freeze
Affiliation:
Keywords: serum transferrin, carbohydrate deficient glycoprotein syndrome, MALDI-TOF-MS, LLO species, Electrospray Ionization Mass Spectrometry
Abstract: The Congenital Disorders of Glycosylation (CDG) are a collection of over 20 inherited diseases that impair protein N-glycosylation. The clinical appearance of CDG patients is quite diverse making it difficult for physicians to recognize them. A simple blood test of transferrin glycosylation status signals a glycosylation abnormality, but not the specific defect. An abnormal trasferrin glycosylation pattern suggests that the defect is in either genes that synthesize and add the precursor glycan (Glc3Man9GlcNAc2) to proteins (Type I) or genes that process the protein-bound N-glycans (Type II). Type I defects create unoccupied glycosylation sites, while Type II defects give fully occupied sites with abnormally processed glycans. These types are expected to be mutually exclusive, but a group of patients is now emerging who have variable coagulopathy and hypoglycemia together with a combination of Type I and Type II transferrin features. This surprising finding makes identifying their defects more challenging, but the defects and associated clinical manifestations of these patients suggest that the N-glycosylation pathway has some secrets left to share.
Export Options
About this article
Cite this article as:
Freeze H. Hudson, Congenital Disorders of Glycosylation: CDG-I, CDG-II, and Beyond, Current Molecular Medicine 2007; 7 (4) . https://dx.doi.org/10.2174/156652407780831548
DOI https://dx.doi.org/10.2174/156652407780831548 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry Editorial
Current Enzyme Inhibition Editorial: (Thematic Issue: Novel Strategies for Cardiac Repair Post-Myocardial Infarction)
Current Pharmaceutical Design Editorial (Thematic Issue: Natural Polyphenols and Diabetes: Understanding their Mechanism of Action)
Current Medicinal Chemistry Hormone Mediation of Immune Responses in the Progression of Diabetes, Rheumatoid Arthritis and Periodontal Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Dosing of Antibiotics in Critically Ill Patients Undergoing Renal Replacement Therapy
Current Pharmaceutical Biotechnology High Plasmatic Levels of Advanced Glycation End Products are Associated with Metabolic Alterations and Insulin Resistance in Preeclamptic Women
Current Molecular Medicine Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies
Recent Patents on Biomarkers Phytochemical Analysis and Antidiabetic Potential of <i>Armoracia Rusticana</i>: Pharmacological and Computational Approach
Combinatorial Chemistry & High Throughput Screening Role of Micronutrients: Boron and Molybdenum in Crops and in Human Health and Nutrition
Current Nutrition & Food Science Diabetes Mellitus: A Potential Target for Stem Cell Therapy
Current Stem Cell Research & Therapy Influence of a High-Fat Diet on Cardiac iNOS in Female Rats
Current Vascular Pharmacology Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry Therapeutic Approaches to Alzheimer’s Type of Dementia: A Focus on FGF21 Mediated Neuroprotection
Current Pharmaceutical Design Subject Index To Volume 12
Current Pharmaceutical Design Importance of Assessing the Effect of Statins on the Function of High- Density Lipoproteins on Coronary Plaque
Cardiovascular & Hematological Disorders-Drug Targets Focused Microarray Analysis: Characterization of Phenomes by Gene Expression Profiling
Current Pharmacogenomics Bioactive Vitamins and Epigenetic Modifications in Diabetes: A Perspective
Current Diabetes Reviews